Skip to main content
Erschienen in:

10.03.2023 | Urologie

Nephrologisches Management und Medikamentendosierung bei Rheumapatienten mit Niereninsuffizienz

verfasst von: Prof. Dr. med. Stefan M. Weiner

Erschienen in: rheuma plus | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Bei Patienten mit entzündlich rheumatischen Erkrankungen und Niereninsuffizienz ergeben sich für den Therapeuten zwei Herausforderungen: die Rheumatherapie an die Nierenfunktion anzupassen und eine nephroprotektive Behandlung durchzuführen, die eine langfristige Verschlechterung der Nierenfunktion verhindert und das erhöhte kardiovaskuläre Risiko reduziert.

Methoden

Mittels Literaturrecherche (PubMed) wurde der aktuelle Wissensstand zur nephroprotektiven Therapie und zur Therapie rheumatischer Erkrankungen bei Niereninsuffizienz erhoben, bewertet und zusammengefasst.

Ergebnisse

Lifestyle-Interventionen, insbesondere die Beendigung eines Nikotinkonsums, und medikamentöse Therapieansätze bilden die Grundlage der Nephroprotektion inklusive Kontrolle des Diabetes mellitus mit Metformin, SGLT2(„sodium glucose transporter 2“)-Inhibitoren, GLP1(„glucagon-like peptide 1“)-Analoga, des Bluthochdrucks mit RAAS(„renin-angiotensin-aldosterone system“)-Blockade, der Hyperlipidämie, der Hyperphosphatämie und metabolischen Azidose. SGLT2-Inhibitoren sind auch bei nichtdiabetischer Nephropathie wirksam. Das erhöhte kardiovaskuläre Risiko wird mittels effektiver Kontrolle der Rheumaaktivität weiter gesenkt. Zahlreiche konventionelle Basismedikamente, insbesondere Methotrexat und die JAK(Januskinase)-Inhibitoren Baricitinib und Filgotinib müssen an die Nierenfunktion meist angepasst werden, während unter den Biologika dies nur für Anakinra der Fall ist. Das erhöhte kardiovaskuläre Risiko bei Niereninsuffizienz limitiert derzeit den Einsatz von Tofacitinib.

Schlussfolgerung

Patienten mit rheumatischen Erkrankungen und Niereninsuffizienz bedürfen einer Anpassung der medikamentösen Therapie und eines komplexen nephroprotektiven Behandlungskonzepts, das im optimalen Fall durch eine enge interdisziplinäre Zusammenarbeit von internistischen Rheumatologen und Nephrologen gewährleisten werden kann.
Literatur
1.
Zurück zum Zitat Abdulaziz N, Shah AR, Mccune WJ (2018) Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 30:249–255PubMedCrossRef Abdulaziz N, Shah AR, Mccune WJ (2018) Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 30:249–255PubMedCrossRef
2.
Zurück zum Zitat Agarwal R, Joseph A, Anker SD et al (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol 33:225–237PubMedPubMedCentralCrossRef Agarwal R, Joseph A, Anker SD et al (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol 33:225–237PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Agarwal R, Sinha AD, Cramer AE et al (2021) Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385:2507–2519PubMedPubMedCentralCrossRef Agarwal R, Sinha AD, Cramer AE et al (2021) Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385:2507–2519PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Anker SD, Butler J, Filippatos G et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143:337–349PubMedCrossRef Anker SD, Butler J, Filippatos G et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143:337–349PubMedCrossRef
5.
Zurück zum Zitat Anonymous (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1–201CrossRef Anonymous (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1–201CrossRef
6.
Zurück zum Zitat Anonymous (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59CrossRef Anonymous (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1–59CrossRef
7.
Zurück zum Zitat Anonymous (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98:S1–S115CrossRef Anonymous (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98:S1–S115CrossRef
8.
Zurück zum Zitat Anonymous (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:S1–S87CrossRef Anonymous (2021) KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99:S1–S87CrossRef
9.
Zurück zum Zitat Badve SV, Pascoe EM, Tiku A et al (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382:2504–2513PubMedCrossRef Badve SV, Pascoe EM, Tiku A et al (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382:2504–2513PubMedCrossRef
10.
Zurück zum Zitat Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377:2181–2192PubMedPubMedCentralCrossRef Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377:2181–2192PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229PubMedCrossRef Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383:2219–2229PubMedCrossRef
12.
Zurück zum Zitat Binda V, Trezzi B, Del Papa N et al (2020) Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J Nephrol 33:1019–1025PubMedCrossRef Binda V, Trezzi B, Del Papa N et al (2020) Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J Nephrol 33:1019–1025PubMedCrossRef
13.
Zurück zum Zitat Bourré-Tessier J, Haraoui B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 37:1416–1421PubMedCrossRef Bourré-Tessier J, Haraoui B (2010) Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol 37:1416–1421PubMedCrossRef
14.
Zurück zum Zitat Bozic M, Diaz-Tocados JM, Bermudez-Lopez M et al (2022) Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant 37:663–672PubMedCrossRef Bozic M, Diaz-Tocados JM, Bermudez-Lopez M et al (2022) Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dial Transplant 37:663–672PubMedCrossRef
15.
Zurück zum Zitat Brandenburg VM, Verhulst A, Babler A et al (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34:408–414PubMedCrossRef Brandenburg VM, Verhulst A, Babler A et al (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34:408–414PubMedCrossRef
16.
Zurück zum Zitat Carriazo S, Sarafidis P, Ferro CJ et al (2022) Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney J 15:845–851PubMedPubMedCentralCrossRef Carriazo S, Sarafidis P, Ferro CJ et al (2022) Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney J 15:845–851PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Chen J, Jin Y, Li C et al (2020) Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: a case report. Medicine 99:e22498PubMedPubMedCentralCrossRef Chen J, Jin Y, Li C et al (2020) Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: a case report. Medicine 99:e22498PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Chou CI, Shih CJ, Chen YT et al (2016) Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. Medicine 95:e2645PubMedPubMedCentralCrossRef Chou CI, Shih CJ, Chen YT et al (2016) Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. Medicine 95:e2645PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Coluzzi F, Caputi FF, Billeci D et al (2020) Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther Clin Risk Manag 16:821–837PubMedPubMedCentralCrossRef Coluzzi F, Caputi FF, Billeci D et al (2020) Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Ther Clin Risk Manag 16:821–837PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Cozzolino M, Minghetti P, Navarra P (2022) Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. J Nephrol 35:863–873PubMedCrossRef Cozzolino M, Minghetti P, Navarra P (2022) Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. J Nephrol 35:863–873PubMedCrossRef
21.
Zurück zum Zitat Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382:2493–2503PubMedPubMedCentralCrossRef Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382:2493–2503PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Evenepoel P, Cunningham J, Ferrari S et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant 36:42–59PubMedCrossRef Evenepoel P, Cunningham J, Ferrari S et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant 36:42–59PubMedCrossRef
23.
Zurück zum Zitat Godron-Dubrasquet A, Woillard JB, Decramer S et al (2021) Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol 36:341–347PubMedCrossRef Godron-Dubrasquet A, Woillard JB, Decramer S et al (2021) Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis. Pediatr Nephrol 36:341–347PubMedCrossRef
24.
26.
Zurück zum Zitat Heerspink HJL, Jongs N, Chertow GM et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:743–754PubMedCrossRef Heerspink HJL, Jongs N, Chertow GM et al (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:743–754PubMedCrossRef
27.
Zurück zum Zitat Hsu CY, Yang W, Parikh RV et al (2021) Race, genetic ancestry, and estimating kidney function in CKD. N Engl J Med 385:1750–1760PubMedPubMedCentralCrossRef Hsu CY, Yang W, Parikh RV et al (2021) Race, genetic ancestry, and estimating kidney function in CKD. N Engl J Med 385:1750–1760PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Idzerda NMA, Pena MJ, Parving HH et al (2019) Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrol Dial Transplant 34:1699–1706PubMedCrossRef Idzerda NMA, Pena MJ, Parving HH et al (2019) Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials. Nephrol Dial Transplant 34:1699–1706PubMedCrossRef
29.
Zurück zum Zitat Ingrasciotta Y, Sultana J, Giorgianni F et al (2015) Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS ONE 10:e122899PubMedPubMedCentralCrossRef Ingrasciotta Y, Sultana J, Giorgianni F et al (2015) Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS ONE 10:e122899PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C‑based equations to estimate GFR without race. N Engl J Med 385:1737–1749PubMedPubMedCentralCrossRef Inker LA, Eneanya ND, Coresh J et al (2021) New creatinine- and cystatin C‑based equations to estimate GFR without race. N Engl J Med 385:1737–1749PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Karasawa K, Ogura S, Takabe T et al (2022) Successful treatment with belimumab in a patient with refractory systemic lupus erythematosus after initiation of hemodialysis: considering the synergistic effect of Belimumab and immunological burn-out phenomenon in end-stage renal disease patients on hemodialysis. Blood Purif 51(2):182–188. https://doi.org/10.1159/000512585CrossRefPubMed Karasawa K, Ogura S, Takabe T et al (2022) Successful treatment with belimumab in a patient with refractory systemic lupus erythematosus after initiation of hemodialysis: considering the synergistic effect of Belimumab and immunological burn-out phenomenon in end-stage renal disease patients on hemodialysis. Blood Purif 51(2):182–188. https://​doi.​org/​10.​1159/​000512585CrossRefPubMed
32.
Zurück zum Zitat Kendrick J, Chonchol M (2011) The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 58:826–834PubMedPubMedCentralCrossRef Kendrick J, Chonchol M (2011) The role of phosphorus in the development and progression of vascular calcification. Am J Kidney Dis 58:826–834PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 92:26–36PubMedCrossRef Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 92:26–36PubMedCrossRef
34.
Zurück zum Zitat Kimura K, Hosoya T, Uchida S et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798–810PubMedCrossRef Kimura K, Hosoya T, Uchida S et al (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798–810PubMedCrossRef
35.
Zurück zum Zitat Kochi M, Kohagura K, Shiohira Y et al (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 71:277–283PubMedCrossRef Kochi M, Kohagura K, Shiohira Y et al (2018) Chronic kidney disease, inflammation, and cardiovascular disease risk in rheumatoid arthritis. J Cardiol 71:277–283PubMedCrossRef
36.
Zurück zum Zitat Krishnaswami S, Chow V, Boy M et al (2014) Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol 54:46–52PubMedCrossRef Krishnaswami S, Chow V, Boy M et al (2014) Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease. J Clin Pharmacol 54:46–52PubMedCrossRef
37.
Zurück zum Zitat Kwon OC, Lee JS, Kim YG et al (2018) Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole. Clin Rheumatol 37:3215–3220PubMedCrossRef Kwon OC, Lee JS, Kim YG et al (2018) Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole. Clin Rheumatol 37:3215–3220PubMedCrossRef
38.
Zurück zum Zitat Lee JS, Oh JS, Kim YG et al (2020) Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 40:765–770PubMedCrossRef Lee JS, Oh JS, Kim YG et al (2020) Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction. Rheumatol Int 40:765–770PubMedCrossRef
39.
Zurück zum Zitat Lee JY, Park JT, Joo YS et al (2021) Association of blood pressure with the progression of CKD: findings from KNOW-CKD study. Am J Kidney Dis 78:236–245PubMedCrossRef Lee JY, Park JT, Joo YS et al (2021) Association of blood pressure with the progression of CKD: findings from KNOW-CKD study. Am J Kidney Dis 78:236–245PubMedCrossRef
40.
Zurück zum Zitat Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMedCrossRef Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254PubMedCrossRef
41.
Zurück zum Zitat Lu JL, Molnar MZ, Naseer A et al (2015) Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 3:704–714PubMedPubMedCentralCrossRef Lu JL, Molnar MZ, Naseer A et al (2015) Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 3:704–714PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432–442PubMedPubMedCentralCrossRef Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432–442PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Ma HY, Chen S, Lu LL et al (2021) Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis. Horm Metab Res 53:730–737PubMedCrossRef Ma HY, Chen S, Lu LL et al (2021) Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis. Horm Metab Res 53:730–737PubMedCrossRef
44.
Zurück zum Zitat Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMedCrossRef Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMedCrossRef
45.
Zurück zum Zitat Major RW, Cheng MRI, Grant RA et al (2018) Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 13:e192895PubMedPubMedCentralCrossRef Major RW, Cheng MRI, Grant RA et al (2018) Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 13:e192895PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Marlow CF, Sharma S, Babar F et al (2018) Severe hypocalcemia and hypomagnesemia with denosumab in advanced chronic kidney disease: case report and literature review. Case Rep Oncol Med 2018:2059364PubMedPubMedCentral Marlow CF, Sharma S, Babar F et al (2018) Severe hypocalcemia and hypomagnesemia with denosumab in advanced chronic kidney disease: case report and literature review. Case Rep Oncol Med 2018:2059364PubMedPubMedCentral
47.
Zurück zum Zitat Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081PubMedPubMedCentralCrossRef Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Mohamed MF, Trueman S, Feng T et al (2019) Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol 59:856–862PubMedPubMedCentralCrossRef Mohamed MF, Trueman S, Feng T et al (2019) Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol 59:856–862PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Mukai M, Kurihara Y, Ito Y et al (2020) Successful treatment with secukinumab of three psoriatic patients undergoing dialysis. J Dermatol 47:e26–e28PubMedCrossRef Mukai M, Kurihara Y, Ito Y et al (2020) Successful treatment with secukinumab of three psoriatic patients undergoing dialysis. J Dermatol 47:e26–e28PubMedCrossRef
51.
Zurück zum Zitat Namour F, Fagard L, Van der Aa A et al (2018) Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol 84:2779–2789PubMedPubMedCentralCrossRef Namour F, Fagard L, Van der Aa A et al (2018) Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol 84:2779–2789PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Navaneethan SD, Shao J, Buysse J et al (2019) Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol 14:1011–1020PubMedPubMedCentralCrossRef Navaneethan SD, Shao J, Buysse J et al (2019) Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis. Clin J Am Soc Nephrol 14:1011–1020PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Naylor KL, Mcarthur E, Leslie WD et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818PubMedCrossRef Naylor KL, Mcarthur E, Leslie WD et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818PubMedCrossRef
55.
Zurück zum Zitat Nissen SE, Yeomans ND, Solomon DH et al (2016) Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:2519–2529PubMedCrossRef Nissen SE, Yeomans ND, Solomon DH et al (2016) Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375:2519–2529PubMedCrossRef
56.
Zurück zum Zitat Ozen G, Pedro S, Michaud K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 48:648–655PubMedCrossRef Ozen G, Pedro S, Michaud K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 48:648–655PubMedCrossRef
57.
Zurück zum Zitat Patel H, Barr A, Jeejeebhoy KN (2009) Renal effects of long-term treatment with 5‑aminosalicylic acid. Can J Gastroenterol 23:170–176PubMedPubMedCentralCrossRef Patel H, Barr A, Jeejeebhoy KN (2009) Renal effects of long-term treatment with 5‑aminosalicylic acid. Can J Gastroenterol 23:170–176PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Paudyal S, Yang FM, Rice C et al (2017) End-stage renal disease in patients with rheumatoid arthritis. Semin Arthritis Rheum 46:418–422PubMedCrossRef Paudyal S, Yang FM, Rice C et al (2017) End-stage renal disease in patients with rheumatoid arthritis. Semin Arthritis Rheum 46:418–422PubMedCrossRef
59.
Zurück zum Zitat Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78:582–589PubMedCrossRef Pazianas M, Miller PD (2021) Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD-MBD): back to basics. Am J Kidney Dis 78:582–589PubMedCrossRef
60.
Zurück zum Zitat Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252–2263PubMedCrossRef Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385:2252–2263PubMedCrossRef
61.
Zurück zum Zitat Puisset F, White-Koning M, Kamar N et al (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76:734–740PubMedPubMedCentralCrossRef Puisset F, White-Koning M, Kamar N et al (2013) Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 76:734–740PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Ridker PM, Macfadyen JG, Glynn RJ et al (2018) Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414PubMedCrossRef Ridker PM, Macfadyen JG, Glynn RJ et al (2018) Inhibition of interleukin-1β by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol 71:2405–2414PubMedCrossRef
63.
Zurück zum Zitat Robinson DE, Ali MS, Pallares N et al (2021) Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res 36:820–832PubMedCrossRef Robinson DE, Ali MS, Pallares N et al (2021) Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res 36:820–832PubMedCrossRef
64.
Zurück zum Zitat Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080PubMedCrossRef Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070–2080PubMedCrossRef
65.
Zurück zum Zitat Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427PubMedCrossRef Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427PubMedCrossRef
66.
Zurück zum Zitat Sato M, Inaba M, Yamada S et al (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39:1082–1090PubMedCrossRef Sato M, Inaba M, Yamada S et al (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39:1082–1090PubMedCrossRef
67.
Zurück zum Zitat Schiffl H, Lang SM, Fischer R (2002) Stopping smoking slows accelerated progression of renal failure in primary renal disease. J Nephrol 15:270–274PubMed Schiffl H, Lang SM, Fischer R (2002) Stopping smoking slows accelerated progression of renal failure in primary renal disease. J Nephrol 15:270–274PubMed
68.
Zurück zum Zitat Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide‑1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575–585PubMedCrossRef Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide‑1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575–585PubMedCrossRef
69.
Zurück zum Zitat Shlipak MG, Tummalapalli SL, Boulware LE et al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99:34–47PubMedCrossRef Shlipak MG, Tummalapalli SL, Boulware LE et al (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99:34–47PubMedCrossRef
70.
Zurück zum Zitat Stahl K, Duong M, Schwarz A et al (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859PubMedPubMedCentral Stahl K, Duong M, Schwarz A et al (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859PubMedPubMedCentral
71.
Zurück zum Zitat Tokoroyama T, Ando M, Setoguchi K et al (2017) Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 32:2035–2042PubMed Tokoroyama T, Ando M, Setoguchi K et al (2017) Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant 32:2035–2042PubMed
72.
Zurück zum Zitat Torres PU, Troya MI, Dauverge M et al (2022) Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought. Nephrol Dial Transplant 37:613–616PubMedCrossRef Torres PU, Troya MI, Dauverge M et al (2022) Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought. Nephrol Dial Transplant 37:613–616PubMedCrossRef
73.
Zurück zum Zitat Umezawa Y, Hayashi M, Kikuchi S et al (2015) Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol 42:731–734PubMedCrossRef Umezawa Y, Hayashi M, Kikuchi S et al (2015) Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol 42:731–734PubMedCrossRef
74.
Zurück zum Zitat Vargas-Santos AB, Peloquin CE, Zhang Y et al (2018) Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 178:1526–1533PubMedPubMedCentralCrossRef Vargas-Santos AB, Peloquin CE, Zhang Y et al (2018) Association of chronic kidney disease with allopurinol use in gout treatment. JAMA Intern Med 178:1526–1533PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Wan EYF, Yu EYT, Chan L et al (2021) Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin J Am Soc Nephrol 16:898–907PubMedPubMedCentralCrossRef Wan EYF, Yu EYT, Chan L et al (2021) Comparative risks of nonsteroidal anti-inflammatory drugs on CKD. Clin J Am Soc Nephrol 16:898–907PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMedCrossRef Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMedCrossRef
77.
Zurück zum Zitat Weckmann G, Chenot JF, Stracke S (2020) The management of non-dialysis-dependent chronic kidney disease in primary care. Dtsch Arztebl Int 117:745–751PubMedPubMedCentral Weckmann G, Chenot JF, Stracke S (2020) The management of non-dialysis-dependent chronic kidney disease in primary care. Dtsch Arztebl Int 117:745–751PubMedPubMedCentral
78.
Zurück zum Zitat Weiner SM, Bergner R (2015) Dosage and toxicity of antirheumatic drugs in renal insufficiency. Z Rheumatol 74:300–309PubMedCrossRef Weiner SM, Bergner R (2015) Dosage and toxicity of antirheumatic drugs in renal insufficiency. Z Rheumatol 74:300–309PubMedCrossRef
79.
Zurück zum Zitat Weiner SM, Waldherr R (2020) Value of renal biopsy in lupus nephritis. Akt Rheumatol 45:319–327 Weiner SM, Waldherr R (2020) Value of renal biopsy in lupus nephritis. Akt Rheumatol 45:319–327
80.
Zurück zum Zitat Wheeler DC, Stefánsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22–31PubMedCrossRef Wheeler DC, Stefánsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22–31PubMedCrossRef
81.
Zurück zum Zitat Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension 71:e13–e115PubMed Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension 71:e13–e115PubMed
82.
Zurück zum Zitat Williams B, Mancia G, Spiering W et al (2018) 2018 practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens 36:2284–2309PubMedCrossRef Williams B, Mancia G, Spiering W et al (2018) 2018 practice guidelines for the management of arterial hypertension of the European society of hypertension and the European society of cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens 36:2284–2309PubMedCrossRef
83.
Zurück zum Zitat Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCrossRef Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCrossRef
84.
Zurück zum Zitat Yamamoto J, Nakazawa D, Nishio S et al (2020) Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study. Ther Apher Dial 24:146–153PubMedCrossRef Yamamoto J, Nakazawa D, Nishio S et al (2020) Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study. Ther Apher Dial 24:146–153PubMedCrossRef
85.
Zurück zum Zitat Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316–326PubMedCrossRef Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316–326PubMedCrossRef
86.
Zurück zum Zitat Zewinger S, Rauen T, Rudnicki M et al (2018) Dickkopf‑3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 29:2722–2733PubMedPubMedCentralCrossRef Zewinger S, Rauen T, Rudnicki M et al (2018) Dickkopf‑3 (DKK3) in urine identifies patients with short-term risk of eGFR loss. J Am Soc Nephrol 29:2722–2733PubMedPubMedCentralCrossRef
87.
Zurück zum Zitat Zewinger S, Speer T, Kleber ME et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25:1073–1082PubMedPubMedCentralCrossRef Zewinger S, Speer T, Kleber ME et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25:1073–1082PubMedPubMedCentralCrossRef
88.
Zurück zum Zitat Zhang Y, Li JJ, Wang AJ et al (2021) Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients. Ren Fail 43:811–820PubMedPubMedCentralCrossRef Zhang Y, Li JJ, Wang AJ et al (2021) Effects of intensive blood pressure control on mortality and cardiorenal function in chronic kidney disease patients. Ren Fail 43:811–820PubMedPubMedCentralCrossRef
Metadaten
Titel
Nephrologisches Management und Medikamentendosierung bei Rheumapatienten mit Niereninsuffizienz
verfasst von
Prof. Dr. med. Stefan M. Weiner
Publikationsdatum
10.03.2023
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 2/2023
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-023-00601-2

Weitere Artikel der Ausgabe 2/2023

rheuma plus 2/2023 Zur Ausgabe